11252 related articles for article (PubMed ID: 19018742)
21. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
22. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D physiology.
Lips P
Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
[TBL] [Abstract][Full Text] [Related]
24. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
25. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.
Massart A; Debelle FD; Racapé J; Gervy C; Husson C; Dhaene M; Wissing KM; Nortier JL
Am J Kidney Dis; 2014 Nov; 64(5):696-705. PubMed ID: 24856872
[TBL] [Abstract][Full Text] [Related]
26. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
[TBL] [Abstract][Full Text] [Related]
27. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
28. Effects of high doses of vitamin D3 and 1,25-dihydroxyvitamin D3 in lactating rats on milk composition and calcium homeostasis of the suckling pups.
Dostal LA; Boass A; Toverud SU
Endocrinology; 1983 May; 112(5):1631-8. PubMed ID: 6299702
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
30. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
31. [Ultrasonography methods in the diagnosis of renal osteodystrophy].
Tomić-Brzac H; Pavlović D
Acta Med Croatica; 2004; 58(1):43-9. PubMed ID: 15125393
[TBL] [Abstract][Full Text] [Related]
32. [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients].
Spiechowicz U; Kokot F; Wiecek A
Przegl Lek; 2003; 60(11):690-4. PubMed ID: 15058034
[TBL] [Abstract][Full Text] [Related]
33. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid hormone increases bone formation and improves mineral balance in vitamin D-deficient female rats.
Toromanoff A; Ammann P; Mosekilde L; Thomsen JS; Riond JL
Endocrinology; 1997 Jun; 138(6):2449-57. PubMed ID: 9165035
[TBL] [Abstract][Full Text] [Related]
35. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.
Minisola S; Cianferotti L; Biondi P; Cipriani C; Fossi C; Franceschelli F; Giusti F; Leoncini G; Pepe J; Bischoff-Ferrari HA; Brandi ML
Osteoporos Int; 2017 Nov; 28(11):3239-3249. PubMed ID: 28815282
[TBL] [Abstract][Full Text] [Related]
36. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
37. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
38. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients.
Caravaca F; Fernández MA; Ruiz-Calero R; Cubero J; Aparicio A; Jimenez F; García MC
Nephrol Dial Transplant; 1998 Oct; 13(10):2605-11. PubMed ID: 9794568
[TBL] [Abstract][Full Text] [Related]
39. The challenge of controlling phosphorus in chronic kidney disease.
Cannata-Andía JB; Martin KJ
Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
